Other Information
−Removed: As disclosed in the table below, during the three months ended June 30, 2025, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
−Removed: Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (a)
−Removed: Total Number of Securities to Be Sold Under the Plan
−Removed: Bassler, Ph.D.
−Removed: 5/2/2025 5/1/2026 5,121
−Removed: (a) The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed
+Added: During the three months ended September 30, 2025, no director or executive officer adopted , modified, or terminated any trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
Exhibit Number Description
−Removed: Restated Certificate of I ncorporation, as amended.
−Removed: Amendment No.
−Removed: 2 to Amended and Restated License and Collaboration Agreement, dated July 27, 2015 and entered into effective as of July 1, 2015, by and between Regeneron Pharmac euticals, Inc.
−Removed: and Sanofi Biotechnology SAS, as successor-in-interest to Aventis Pharmaceuticals, Inc.
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
3 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the registrant's Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024;
−Removed: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2025 and 2024;
−Removed: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024;
−Removed: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024;
+Added: (i) the registrant's Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024;
+Added: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2025 and 2024;
+Added: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2025 and 2024;
+Added: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024;
and (v) the notes to the registrant's Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
−Removed: * Certain confidential portions of this Exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.
−Removed: The registrant agrees to furnish supplementally a copy of all confidential portions of this Exhibit that were omitted to the SEC upon its request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
REGENERON PHARMACEUTICALS, INC.
−Removed: August 1, 2025 By:
+Added: October 28, 2025 By:
/s/ Christopher Fenimore
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.